Lexaria Bioscience Corp (LEXXW) - Total Liabilities
Based on the latest financial reports, Lexaria Bioscience Corp (LEXXW) has total liabilities worth $1.53 Million USD as of November 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LEXXW net assets growth trend to track the company's year-over-year net asset growth rate.
Lexaria Bioscience Corp - Total Liabilities Trend (2005–2025)
This chart illustrates how Lexaria Bioscience Corp's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Lexaria Bioscience Corp to measure how efficiently the company converts operating cash flow to free cash.
Lexaria Bioscience Corp Competitors by Total Liabilities
The table below lists competitors of Lexaria Bioscience Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ordinary Fully Paid Deferred Settlement
AU:1TTDB
|
Australia | AU$243.99K |
|
Clene Inc
NASDAQ:CLNNW
|
USA | $34.67 Million |
|
Hall of Fame Village LLC
NASDAQ:HOFVW
|
USA | $325.72 Million |
|
Jasmine International Public Company Limited
F:JASN
|
Germany | €7.08 Billion |
|
Aquis Exchange PLC
LSE:AQX
|
UK | GBX7.47 Million |
|
BriaCell Therapeutics Corp
NASDAQ:BCTXW
|
USA | $3.35 Million |
|
Ucommune International Ltd
NASDAQ:UKOMW
|
USA | $173.94 Million |
|
immatics biotechnologies GmbH
NASDAQ:IMTXW
|
USA | $105.09 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Lexaria Bioscience Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Lexaria Bioscience Corp.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lexaria Bioscience Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lexaria Bioscience Corp (2005–2025)
The table below shows the annual total liabilities of Lexaria Bioscience Corp from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-08-31 | $1.57 Million | +30.08% |
| 2024-08-31 | $1.21 Million | +199.26% |
| 2023-08-31 | $403.91K | +100.51% |
| 2022-08-31 | $201.44K | -0.90% |
| 2021-08-31 | $203.26K | -41.25% |
| 2020-08-31 | $345.98K | +87.52% |
| 2019-08-31 | $184.51K | +322.79% |
| 2018-08-31 | $43.64K | -52.74% |
| 2017-08-31 | $92.35K | -80.72% |
| 2016-08-31 | $478.88K | +768.72% |
| 2015-08-31 | $55.12K | -96.26% |
| 2014-08-31 | $1.47 Million | 0.00% |
| 2013-08-31 | $1.47 Million | +1.14% |
| 2012-08-31 | $1.46 Million | -13.12% |
| 2011-08-31 | $1.68 Million | +13.67% |
| 2010-08-31 | $1.48 Million | +21.68% |
| 2009-08-31 | $1.21 Million | +53.92% |
| 2008-08-31 | $788.18K | +96.56% |
| 2007-08-31 | $400.98K | -80.10% |
| 2006-08-31 | $2.01 Million | +17928.53% |
| 2005-08-31 | $11.18K | -- |
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more